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A B S T R A C T
Background
Chronic renal failure patients are at particular risk of hepatitis B virus infection. Early studies have demonstrated that renal failure
patients benefit from vaccination; however, not all studies have consistently shown benefit.
Objectives
To determine the beneficial and harmful effects of hepatitis B vaccine and of a reinforced vaccination series in chronic renal failure
patients.
Search methods
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Renal Group Controlled Trials Register, The
Cochrane Controlled Trials Register on The Cochrane Library (Issue 1, 2002), PubMed/MEDLINE (1966 to July 2003), EMBASE (1985
toNovember 2003), Current Clinical Practice Guidelines (Canadian Immunization Guide and Vaccine Preventable Diseases Surveillance
Manual), and Science Citation Index as well as journals, published abstracts, and reference lists of articles.
Selection criteria
Randomised clinical trials comparing plasma vaccine with placebo, recombinant vaccine with placebo, recombinant vaccine with plasma
vaccine, and a reinforced vaccination series (ie, more than three inoculations) with three inoculations of vaccine in chronic renal failure
patients.
Data collection and analysis
Primary outcome measures included incidence of patients developing hepatitis B virus antibodies and infections while secondary
outcomes included adverse events, liver-related morbidity, and mortality. Random effects models were used and reported relative risks
and 95% confidence intervals (RR and 95% CI).
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Main results
We included seven randomised clinical trials. None of them had high quality. Plasma vaccine was significantly more effective than
placebo in achieving hepatitis B antibodies (RR 23.0, 95% CI 14.39 to 36.76, 3 trials). We found no statistically significant difference
between plasma vaccine or placebo regarding hepatitis B virus infections (RR 0.50, 95% CI 0.20 to 1.24). We found no statistically
significant differences between recombinant vaccine and plasma vaccine in achieving hepatitis B antibodies (RR 0.65, 95% CI 0.28 to
1.53, 2 trials). Heterogeneity was significant and appeared to be attributable to the dose of vaccine. Two trials examined a reinforced
recombinant vaccine strategy, which was not statistically more effective than three inoculations of recombinant vaccine regarding
development of hepatitis B antibodies (RR 1.36, 95% CI 0.85 to 2.16).
Authors’ conclusions
Plasma derived vaccines are more effective than placebo in achieving hepatitis B antibodies, while no statistically significant difference
was found between recombinant and plasma vaccines. No statistically significant difference of effectiveness was observed between a
reinforced vaccination series versus routine vaccinations of three inoculations of recombinant vaccine.
P L A I N L A N G U A G E S U M M A R Y
Hepatitis B vaccines achieve antibody production in patients with chronic renal failure, but we do not know if the vaccines are
protective
Patients with chronic renal failure are at increased risk of hepatitis B virus infections. This review was undertaken to determine the
beneficial and harmful effects of vaccination against hepatitis B and of a reinforced recombinant vaccination series. None of the trials
had high methodological quality. Plasma vaccine was significantly more effective than placebo in achieving hepatitis B antibodies. Yet
no statistically significant difference was found between the use of plasma vaccine or placebo in preventing hepatitis B virus infections.
No trials comparing recombinant vaccine with placebo were identified. There was no significant difference between recombinant and
plasma vaccines or between a reinforced vaccination series and routine vaccinations of three inoculations using recombinant vaccine
regarding achieving hepatitis B antibodies.
B A C K G R O U N D
Hepatitis B virus (HBV) is one of the most frequent viral infec-
tions in humans with estimates of 200 to 500 million infected
people worldwide (Specter 1999; Fabrizi 2000). Infection can oc-
cur either through perinatal transmission, which is the cause of 35
to 40 per cent of new infections worldwide (Fabrizi 2000) or hor-
izontally through exposure to infected blood or other body fluids.
While the perinatal (vertical) mode of transmission is of increas-
ing concern in specific geographic regions (Fabrizi 2000) much
more attention has been focused on the horizontal transmission of
the HBV among high-risk populations. The high-risk population
for horizontal transmission includes health-care workers, chronic
renal failure (CRF) patients (Torres 1996; Jefferson 2000), and
homosexual men (MacKellar 2001).
CRF patients are at particular risk of HBV infection due to their
increased exposure to blood products, haemodialysis (Crosnier
1981; Desmyter 1983; Jilg 1986a; Seaworth 1988a; Dukes 1993;
El-Reshaid 1994; Jungers 1994a), and an impaired immune
response (Revillard 1979; Chatenoud 1986; Chatenoud 1990;
Johnson 1992). The impaired immune response affects hepatitis
B vaccine efficacy. Cases of infections among renal patients un-
dergoing dialysis are generally mild, but up to 80 per cent may
progress into chronic carriers. This poses risk to other haemodialy-
sis recipients in the same clinical facility (Desmyter 1983; Stevens
1984; Huang 1997). Liver-related morbidity including cirrho-
sis and hepatocellular carcinoma may also develop. Occurrences
of chronic hepatitis in the haemodialysed populace have ranged
from 3 to 29 per cent (Huang 1997) and the estimated prevalence
of HBV infection has previously been reported to be 1.1 to 6.1
per cent in dialysis patients worldwide (Geerlings 1991; Petrosillo
1993; Tokars 1998). Current data from the United States indi-
cate that the prevalence of HBV infections among those receiving
maintenance haemodialysis is 0.9 per cent (Tokars 2000) while
the prevalence of HBV infections among dialysis patients in the
developing world range from 12 to 21.6 per cent (Fabrizi 2001).
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Transmission of hepatitis B may be prevented through the admin-
istration of hepatitis B vaccine to persons at risk. The first hep-
atitis vaccine was derived from pooled hepatitis B surface antigen
positive plasma and was licensed in the United States of America
in 1981 (Fabrizi 2000). Today, recombinant vaccines have largely
replaced it (Jilg 1986a; El-Reshaid 1994; Zannolli 1997).
Vaccination efficacy of hepatitis B vaccine may be determined by
measuring the serum titres of antibody to the hepatitis B surface
antigen (HBsAg). Seroconversion can be used as surrogate marker
for protection against hepatitis B (Popper 1990). Titres greater
than 10 milli international units per millilitre (mIU/mL, ie, 10
IU/L) or greater than 10 Sample Ratio Units (SRU) are gener-
ally considered protective (Popper 1990). While seroconversion is
generally a useful surrogate marker, for some populations it may
be inadequate thus necessitating the study of both seroconversion
and HBV infections. A systematic review of effectiveness of these
vaccines in health-care workers (Jefferson 2000) has shown ben-
efits. Early studies have demonstrated that renal-failure patients
benefit from vaccination. However, many have incomplete sero-
conversion with rates ranging from 32 to 80 per cent, and not all
studies have consistently shown benefit (Fabrizi 2000). The Advi-
sory Committee on Immunization Practices recommends a four-
dose schedule of recombinant Engerix B (40 µg) vaccine in renal
patients over 20 years of age (Rangel 2000). The current Center
for Disease Control (CDC) recommendations for vaccination of
renal patients over 20 years of age also specifies a four dose recom-
binant vaccine schedule of 40 µgEngerix B at 0, 1, 2, and 6months
(CDC 2001). Various strategies employed in HBV vaccination
in this population include increased doses of vaccine, reinforced
vaccination strategies, and different schedules of vaccine admin-
istration (Jilg 1986a; Seaworth 1988a; El-Reshaid 1994). Trials
which have investigated variations in vaccine dose, dose schedul-
ing, and the use of adjuvants to enhance seroconversion rates have
had variable results (Fabrizi 2000). Thus the optimum strategy for
immunizing CRF patients is not clear.
We have been unable to identify systematic reviews or meta-anal-
yses on hepatitis B vaccination for CRF patients. This systematic
review investigates the effectiveness and safety of hepatitis B vacci-
nation in providing adequate seroconversion in CRF patients and
preventing hepatitis B infections.
O B J E C T I V E S
• To identify the beneficial and harmful effects of hepatitis B
vaccine in CRF patients.
• To identify the beneficial and harmful effects of a reinforced
vaccination series (three inoculations plus one or more booster
inoculations) against a vaccination series of three inoculations
using hepatitis B vaccine.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Inclusion criteria
• Randomised clinical trials studying the administration of
hepatitis B vaccine to CRF patients, with or without dialysis.
• No language, publication date, or publication status
restrictions were imposed.
Exclusion criteria
• Quasi-randomised trials.
Types of participants
Inclusion criteria
• Participants of any age with CRF or receiving dialysis
(haemodialysis or peritoneal dialysis) were considered. CRF was
defined as serum creatinine greater than 200 µmol/L for a period
of more than six months or individuals receiving dialysis
(haemodialysis or peritoneal dialysis).
• Participants who were seronegative for HBsAg and
seronegative for anti-HBsAg antibodies or unsuccessfully
vaccinated against HBV (< 10 SRU, < 10 mIU/mL, < 10 IU/L,
or equivalent) (Popper 1990; Alexander 1998) prior to vaccine
administration were included (See Additional Tables 01 and 02).
Exclusion criteria
• Renal transplant patients were excluded from this review as
these individuals are immunosuppressed and are receiving
immunosuppressant agents to prevent rejection of their
transplanted organs (Johnson 1992; Lefebure 1993; Huang
1997; Fivush 1998), and they have essentially normal renal
function (Feuerhake 1984).
• Participants infected with the HBV or with evidence of
potential infection (elevated transaminases) were excluded.
Types of interventions
Inclusion criteria
• Trials comparing the beneficial and harmful effects of
hepatitis B vaccines with adjuvant or cytokine co-interventions.
• Trials comparing the beneficial and harmful effects of
immunoglobulin prophylaxis. This review was limited to studies
looking at active immunization.
• Hepatitis B vaccines (plasma or recombinant (yeast)
derived) of all types, dose, and regimens versus placebo, control
vaccine, or no vaccine.
• Reinforced schedules of vaccine of three inoculations plus
one or more booster inoculations versus standard vaccination
with three inoculations of vaccine.
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Types of outcome measures
Primary outcome measures
• Seroconversion, ie, proportion of patients with adequate
anti-HBs response (> 10 IU/L or SRU) (Table 1; Table 2).
• Hepatitis B infections (as measured by hepatitis B core
antigen (HBcAg) positivity or persistent HBsAg positivity), both
acute and chronic. Acute (primary) HBV infections were defined
as seroconversion to HBsAg positivity or development of IgM
anti-HBc. Chronic HBV infections were defined as the
persistence of HBsAg for more than six months or HBsAg
positivity and liver biopsy compatible with a diagnosis or chronic
hepatitis B.
Secondary outcome measures
• Adverse events of hepatitis B vaccinations were recorded
and were categorized as:
i) Local injection-site adverse events (as defined in included stud-
ies).
ii) Systemic adverse events.
• Liver-related morbidity (elevated transaminases, cirrhosis,
hepatocellular carcinoma).
• Mortality.
Where outcomes were reported at various intervals during the ran-
domised trials, we analysed the outcomes reported at the longest
period following vaccinations.
Search methods for identification of studies
• We searched The Cochrane Hepato-Biliary Group Controlled
Trials Register, The Cochrane Renal Group Controlled Trials
Register, and The Cochrane Controlled Trials Register (Cochrane
Library Issue 1, 2002) were searched.
• We conducted electronic searches utilizing PubMed/
MEDLINE (1966 to July 2003) and EMBASE (Excerpta Medica
Database) (1985 to 2003) databases (see Appendix 1 for the
search strategies and MESH terms utilized). Both MESH and
non-MESH terms were used.
• We searched Science Citation Index (Web of Science)
utilizing search terms similar to those used for the PubMed/
MEDLINE and EMBASE searches.
• We searched published abstracts and proceedings from key
scientific conferences of renal, hepatology, and immunology
societies to identify any trials not published in journal format.
This included the Journal American Society of Nephrology,
Nephrology Dialysis Transplant - European Dialysis Transplant
Association,Hepatology, Journal of Hepatology,American Association
for the Study of Liver Diseases, and Vaccine from 1980 to 2002.
• We searched current clinical practice guidelines (Canadian
Immunization Guide and Vaccine Preventable Diseases Surveillance
Manual) for relevant randomised clinical trials.
• We hand searched reference lists from review articles
retrieved from PubMed/MEDLINE and reference lists from
randomised clinical trials to identify additional trials.
Data collection and analysis
Application of inclusion criteria
Weconducted this systematic review and reportedfindings accord-
ing to the ’Quality of reporting ofmeta-analysis guidelines’ (QUO-
RUM) (Moher 1999; Walker 1999) and according to the recom-
mendations of The Cochrane Collaboration in The Cochrane Re-
viewers’ Handbook (Clarke 2001).
• We assessed titles of research articles retrieved from the
electronic database and hand searches to determine which
abstracts should be reviewed for possible inclusion as per the
reviewers defined eligibility criteria described under ’Types of
studies’, ’Types of participants’, ’Types of interventions’, and
’Types of outcome measures’.
• All abstracts were assessed using the eligibility criteria
proposed by the reviewers for selecting papers.
• We listed excluded trials with the reasons for exclusion.
• We resolved discrepancies between individual reviewers
through consensus.
Data extraction
We performed data extraction on all randomised clinical trials
meeting eligibility criteria and review objectives. To ensure accu-
racy, a minimum of three reviewers independently extracted data
from each trial.
Data extraction included:
(1) Number of participants in each randomised controlled trial
and the number enrolled to receive each intervention.
(2) Demographic composition and baseline clinical information
for each intervention group. This included, when specified, age,
gender, stage of renal disease, dialysis status (haemodialysis, peri-
toneal dialysis, and average number of years on dialysis), previ-
ous vaccination status (previous vaccination attempts, previously
unvaccinated, or unknown), previous antigen status before receiv-
ing trial intervention (HBsAg negative, anti-HBsAg negative), and
participant withdrawals or dropouts.
(3) Types of interventions employed (plasma vaccine versus
placebo, recombinant vaccine versus plasma vaccine, reinforced
vaccination series (three inoculations plus one or more booster
inoculations)) versus standard vaccination series (three inocula-
tions).
(4) Information relating to the vaccines (or placebo), the trade
name, dose, number of doses utilized in the trial, the immunization
schedules utilized (in months, with first inoculation = 0 months),
and route of vaccination if indicated.
(5) Information concerning the primary outcomes utilized in each
included randomised clinical trial, the type of immunoassay em-
ployed, and the time of assessment of outcomes.
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(6) Primary outcomes collected included the definition of serocon-
version in each trial (SRU or IU/L) and the number seroconverted
in each group, the definition of partial seroconversion, and the
number partially seroconverted if given, and the number of active
hepatitis B infections in each group (both acute and chronic).
(7) Secondary outcomes collected included the number of adverse
events, deaths, and liver-related morbidity.
Methodological quality
The methodological quality, defined as the confidence that the
design and report will restrict bias in the intervention compari-
son (Moher 1998), was evaluated independently and unblinded
by a minimum of two reviewers. According to empirical evidence
(Schulz 1995; Jadad 1996; Kjaergard 2001; Jüni 2001), we as-
sessed the methodological quality of all randomised clinical trials
meeting the criteria and objectives of this review by using separate
components, ie, generation of the allocation sequence, allocation
concealment, blinding, follow-up, and use of intention-to-treat
analyses. Components were assessed as adequate, unclear, or inad-
equate:
(1) Generation of the allocation sequence: adequate (computer
generated random numbers or similar), or unclear (not described),
or inadequate (other methods).
(2) Allocation concealment: adequate (central independent unit,
sealed envelopes, or similar), or unclear (not described), or inade-
quate (open table of random numbers or similar). In the Table of
Characteristics of Included Studies A = adequate, B = unclear, C
= inadequate.
(3) Blinding: adequate (double blind (blinding of both partici-
pants and investigators) and identical placebo tablets or similar),
or unclear (not described), or not performed (tablets versus injec-
tions, or similar).
(4) Follow-up: adequate (number and reasons for dropouts and
withdrawals described), or unclear (if the report gave impression
that there had been no dropouts or withdrawals, but this was not
specifically stated), or inadequate (number or reasons for dropouts
and withdrawals were not described).
Statistical analysis
We entered data extracted from included randomised controlled
trials into Review Manager 4.2.6. software for statistical analysis.
The random effects model was used. Data synthesis was carried
out as follows:
- Relative risk and 95% confidence intervals were computed.
- Chi-squared testing for heterogeneity was performed. A P value
of 0.1 was selected (Engels 2000).
- Homogeneity of interventions, participants, and outcomes was
assessed prior to combining extracted data from different included
randomised clinical trials being compared.
- Variability among trial results was expected, and possibilities in-
cluded dose, route, frequency, and timing of vaccine administra-
tion, along with the populations reported, and the length of fol-
low-up.
- Significant heterogeneity encountered required explanation by
the reviewers.
- The reviewers exercised caution when facing the dilemma of low
methodological quality for a significant number of included trials.
- The results were analysed with intention-to-treat analyses to
study beneficial effects.
- Where comparisons involved a small number of included trials,
caution was exercised when interpreting meta-analyses..
- ’Subgroup analysis’ was performed in cases where comparisons
between interventions being considered demonstrated significant
heterogeneity.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Following the PubMed electronic database search using the search
strategy (Appendix 1), we conducted a title search on 954 listed
citations, of which 171 abstracts were reviewed. We retrieved one
hundred eight full text journal articles including both trials (n =
75) and review articles (n = 33). Only 12 articles were randomised
clinical trials that met the criteria for this review. These articles
described a total of seven randomised trials.
We conducted a subsequent modified search strategy to detect
randomised clinical trials in PubMed,which resulted in 23 unique
trials. We then reviewed titles and abstracts of these and obtained
five full text articles. However, none met the inclusion criteria.
We searched reference lists of identified journal articles but did
not identify any additional trials meeting our inclusion criteria.
An electronic search of EMBASE retrieved 772 titles, of which
102 abstracts were reviewed. Eighty-six full articles were reviewed;
however, none met our inclusion criteria.
TheWeb of Science electronic search (Science Citation Index) pro-
duced 10 titles of which four abstracts were reviewed. No unique
randomised trials were found.
Thus we excluded a total of seven randomised clinical trials from
this review while another seven met the specified objectives and
inclusion criteria. Three trials investigated plasma vaccines versus
placebo (Crosnier 1981;Desmyter 1983; Stevens 1984). Two trials
investigated the comparison of recombinant and plasma vaccines
(Jungers 1994a; Seaworth 1988a). Another two trials compared
a reinforced schedule of recombinant vaccine with a vaccination
series of three inoculations of recombinant vaccine (El-Reshaid
1994; Jilg 1986a) (See Table of Characteristics of Included Stud-
ies).
Plasma derived hepatitis B vaccine versus placebo
Crosnier 1981
This randomised, double-blinded, placebo-controlled trial re-
ported the use of plasma vaccine (Institut Pasteur Production Vac-
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cine) 5 µg versus placebo, both administered at 0, 1, and 2months.
Participants were haemodialysis patients. Outcomes included se-
roconversion, HBV infections, and adverse events at 12 months.
Desmyter 1983
This randomised, double-blinded, and placebo-controlled inves-
tigated heat-inactivated (CLB) plasma vaccine 3 µg versus placebo
for haemodialysis recipients. Inoculations were performed at 0, 1,
2, and 4 months. Outcomes included seroconversion, partial sero-
conversion, HBV infections, and adverse events at approximately
14 months.
Stevens 1984
This randomised trial of haemodialysis patients involved the com-
parison of Heptavax B vaccine 40 µg at 0, 1, and 6 months against
placebo. Outcomes reported included seroconversions and HBV
infections at 24 months.
Recombinant vaccine versus plasma vaccine
Jungers 1994
This randomised trial involved chronic uremic patients. Gen-
Hevac B (recombinant) vaccine 20 µg with inoculations occurring
at 0, 1, 2, 4, and 12 months was compared with Hevac B (plasma)
vaccine 5 µg at 0,1,2,4, and 12 months. Outcomes included both
seroconversions and partial seroconversions at 12 months.
Seaworth 1988a
This randomised trial involved CRF patients. This trial compared
recombinant and plasma vaccines. Recombivax vaccine 20 µg ad-
ministered at 0,1,and 6 months was compared with Heptavax B
(plasma) vaccine 40 µg at 0, 1, 6 months. Another comparison
involved Recombivax 40 µg at 0, 1, 6 months against Heptavax B
40 µg at 0, 1, and 6months.We divided the data of the plasma vac-
cine arm in half in order to undertake the statistical comparisons.
Both seroconversions and partial seroconversions at 12 months
were reported.
Reinforced vaccination series versus three inoculation vacci-
nation series
El-Reshaid 1994
This was a randomised, single-blinded trial assessing a reinforced
vaccination series (three inoculations plus one or more booster in-
oculations) against a vaccination series of three inoculations using
recombinant hepatitis B vaccine. Participants were on either peri-
toneal dialysis or haemodialysis. Engerix B 40 µg was administered
at 0, 1, and 6 months for one arm, while another arm received
Engerix B 40 µg at 0, 1, 2, and 6 months. This study also involved
an arm of participants receiving Engerix B 20 µg at 0, 1, 2, and 6
months but this arm was excluded for the purposes of this review.
Outcomes assessed included seroconversion at 24 months.
Jilg 1986a
This study was randomised and involved dialysis patients. Three
intervention groups were employed, assessing a primary vaccina-
tion series of three inoculations against two reinforced vaccination
campaigns utilizing a booster inoculation. Merck Sharp Dohme
recombinant vaccine 40 µg at 0, 1, and 6 months was compared
to the same vaccine dose using the schedule 0, 1, 2, 3, 4, and
5 months and to Merck Sharp Dohme recombinant vaccine 20
µg at 0, 1, 2, 3, 4, and 5 months. We divided the data of the
three inoculations arm in half in order to undertake the statistical
comparisons. Outcomes reported included seroconversions at 10
months.
Risk of bias in included studies
The methodological quality of the included trials is described in
Table 3. Of the seven trials, none reported on the generation of
the allocation sequence, although the Desmyter 1983 trial de-
scribed a code used for the generation of the allocation sequence.
However, this information was found to be insufficient to de-
termine the appropriateness of the generation of the allocation
sequence. The allocation concealment was unclear in six trials,
but one (Desmyter 1983) was found to have adequate allocation
concealment. Three trials were double blinded and used placebo
(Crosnier 1981; Desmyter 1983; Stevens 1984), and the remain-
ing four were conducted without blinding. In five trials the num-
ber and reason for dropouts and withdrawals were either described
(Desmyter 1983; Seaworth 1988a; Stevens 1984) or mentioned
(Crosnier 1981; Jungers 1994a). The El-Reshaid 1994 trial had
given the number of dropouts and withdrawals but did not pro-
vide explanations for these occurrences, while the Jilg 1986a trial
completely failed to discuss participant withdrawals or dropouts.
The assessed methodological quality of the Jilg 1986a and El-
Reshaid 1994 studieswas very lowand the assessedmethodological
quality of Jungers 1994a and Seaworth 1988a was equivalent, with
both receivingmodest scores. Accordingly, none of the trials was of
high methodological quality, ie, having adequate generation of the
allocation sequence, allocation concealment, blinding, and follow-
up. However, as the important study outcomes were well-defined
serologic responses and HBV infections, inadequate blinding may
be of less concern.
Effects of interventions
Plasma derived hepatitis B vaccine versus placebo
Rate of seroconversion
Three randomised clinical trials analysed the effectiveness of
plasma derived vaccine versus placebo with 933 persons receiving
plasma vaccine and 917 receiving placebo vaccination (Crosnier
1981; Desmyter 1983; Stevens 1984). Vaccination with plasma
derived vaccine was found to be statistically more effective than
placebo in achieving seroconversion and yielded a RR 23.00, 95%
CI 14.39 to 36.76 (Comparison 01-01). The results were homo-
geneous (chi square = 0.36, df = 2, P = 0.83).
Only one trial provided sufficient information on partial serocon-
versions (Desmyter 1983) and indicated that partial seroconver-
sions were greater among those in the plasma vaccine group (RR
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21.52, 95% CI 10.89 to 42.53, P < 0.00001 (Comparison 01-
02)).
Hepatitis B infections
The use of plasma derived hepatitis B vaccine did not differ sig-
nificantly from placebo in preventing active HBV infections and
yielded a RR 0.50, CI 0.20 to 1.24 (Comparison 01-03) although
a trend was seen in the direction of protection, with two studies
showing benefit (Crosnier 1981; Desmyter 1983). However, the
analysis also revealed significant heterogeneity (chi squared value
of 12.29, df = 2, P = 0.0021). Sensitivity analyses were performed
on the data from the three trials to identify a possible source of
the heterogeneity. One of the trials had a significantly larger pop-
ulation of persons, utilized larger dosages of vaccine, and assessed
hepatitis outcomes at two years (Stevens 1984) while the other
two trials conducted assessments at 12 and 14 months (Crosnier
1981; Desmyter 1983). The source of plasma vaccines also dif-
fered between the studies.
Adverse events and deaths
Two trials reported adverse events and deaths (Crosnier 1981;
Desmyter 1983). The use of plasma vaccine appeared to be well
tolerated with no significant increase in deaths or adverse events.
Both the group receiving plasma vaccine and the group receiving
placebo reported a large number of adverse events presumed to be
unrelated to the use of hepatitis B vaccine (Desmyter 1983) .
Recombinant versus plasma derived hepatitis B vaccine
Rate of seroconversion
Two randomised trials comparing recombinant versus plasma de-
rived hepatitis B vaccines met the inclusion criteria (Seaworth
1988a; Jungers 1994a). A total of 101 participants were inoculated
with recombinant derived hepatitis B vaccine and 80 with plasma
derived vaccine. One study (Seaworth 1988a) involved two sepa-
rate comparisons of recombinant vaccine, of differing dosages, to
plasma vaccine. For the purposes of this review, we treated these
two comparisons as separate studies and therefore we differenti-
ated them by Seaworth 1988a and Seaworth 1988b. We halved
the control group data. Although the use of recombinant vaccine
was less effective in producing seroconversions than plasma de-
rived vaccine, the difference was not significant (RR 0.65, 95%CI
0.28 to 1.53 (Comparison 02-01). Heterogeneity was significant
(chi square = 10.22, df = 2, P = 0.006).
We conducted sensitivity analyses to determine possible origins
of the heterogeneity. Combining the two recombinant groups in
Seaworth 1988a together to compare vaccine effectiveness, regard-
less of the dose of recombinant vaccine used, still tended to favour
the use of plasma vaccine, although this was not significant (RR
0.75, 95% CI 0.29 to 1.92 (Comparison 02-03)). Heterogeneity
also remained high (chi square = 9.02, df = 2, P = 0.0027). When
only the high dose of recombinant vaccine arm in Seaworth 1988a
was used to compare plasma and recombinant vaccines, hetero-
geneity was eliminated (chi square = 2.61, df = 1, P = 0.11) and
yielded a RR 0.96, 95% CI 0.58 to 1.57 (Comparison 02-04).
Comparison of partial and full seroconversions did not favour
the use of recombinant derived vaccine over plasma vaccine and
yielded a RR value of 0.97, 95% CI 0.69 to 1.38 (Comparison
02-02). This comparison also demonstrated homogeneity among
the studies (chi square = 3.88, df = 2, P = 0.14).
Hepatitis B infections
There was insufficient information reported in the studies of
Seaworth 1988a and Jungers 1994a to assess whether recombi-
nant vaccines differed from plasma derived vaccines in preventing
hepatitis B infections.
Adverse events and deaths
There was insufficient information reported in the studies of
Seaworth 1988a and Jungers 1994a to assess deaths and adverse
events from receiving recombinant or plasma vaccines.
Reinforced recombinant vaccination series versus three recom-
binant vaccine inoculations
Rate of seroconversion
Two randomised trials compared the effectiveness of a reinforced
vaccination series with three inoculations of recombinant hepati-
tis B vaccine (Jilg 1986a; El-Reshaid 1994). In total 63 partici-
pants received a reinforced series of recombinant vaccine while 43
received three inoculations. One study (Jilg 1986a) involved two
separate comparisons of three inoculations of 40 µg to six inocula-
tions of 20 µg and six inoculations of 40 µg to three inoculations of
40 µg. These two separate comparisons within the same studywere
differentiated by the use of an asterisk (Jilg 1986a; Jilg 1986b).We
halved the control group data. The initial analysis yielded a RR
1.36, 95% CI 0.85 to 2.16 (Comparison 03-01) and indicated
that the reinforced series was not significantly more effective in
achieving seroconversions than three inoculations. However, only
106 patients were studied and the possibility of a type II error
cannot be excluded. Heterogeneity was insignificant (chi square =
2.59, df = 2, P = 0.27).
Hepatitis B infections
Insufficient data existed to assess whether a reinforced vaccination
series was superior to a series of three inoculations of recombinant
hepatitis B vaccine in preventing hepatitis B infections.
Adverse events and death
There was insufficient information reported in these two trials (Jilg
1986a; El-Reshaid 1994) to assess deaths and adverse events.
D I S C U S S I O N
This is the first systematic review of the effectiveness of hepatitis
B vaccinations in CRF patients. Seroconversion following hepati-
tis B vaccination can be used as surrogate marker for protection
against hepatitis B (Popper 1990). The results of this review indi-
cate that the use of plasma derived vaccine is effective in achiev-
ing seroconversion. However, reductions in HBV infections could
not be demonstrated in this population given the wide confi-
dence intervals, the heterogeneity, and the non-significant overall
effect. Plasma vaccine is significantly more effective than placebo
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in achieving seroconversion. Recombinant vaccine may be as ef-
fective as plasma vaccine in achieving seroconversion. A significant
benefit to the use of a reinforced recombinant vaccination series
in patients with CRF over the use of three inoculations could not
be proven.
Despite a thorough search of the literature we found only seven
randomised trials matching the inclusion criteria selected for this
review. Although the search for relevant literature was extensive,
publication bias cannot be disregarded, as trials with negative re-
sults may have been less likely to be published.While the relatively
small number of included trials is a limitation of this review, the
comparisons between the use of plasma vaccine and placebo in-
volved a large number of participants (n = 1850) (Crosnier 1981;
Stevens 1984). The included trials may not have been designed
with sufficient power to detect statistically significant differences
between HBV infections in the plasma and placebo groups as in-
fection rates were low in some of the studies (Stevens 1984). As
infections occurred in those who had previously seroconverted, se-
roconversion may not be universally protective in renal failure pa-
tients (Stevens 1984). In addition, the mean period of haemodial-
ysis did differ between Crosnier 1981 and Stevens 1984, as partic-
ipants in the Stevens 1984 trial had been receiving haemodialysis
for a longer duration than those in the other trial (vaccine groups
9.9 ± 13.1 months (Crosnier 1981) and 2.1± 2.1 years (Stevens
1984), placebo groups 6.9 ± 8.6 months (Crosnier 1981) and 2.0
± 2.3 years (Stevens 1984)).
Two randomised trials compared recombinant derived vaccine
with plasma derived vaccine (Jungers 1994a; Seaworth 1988a).
Both of these trialswere deemed tobe of the same, but lowmethod-
ological quality and both had inadequate allocation concealment.
These two trials had far fewer participants than the trials compar-
ing plasma vaccine with placebo. One of the two studies involved
the use of two different doses of Recombivax vaccine (20 µg and 40
µg) (Seaworth 1988a). For the purpose of this analysis the plasma
arm from this study was used in two different comparisons, which
might have introduced bias into the final analysis, although the
number of participants was halved. There was significant hetero-
geneity between the two studies in this comparison. These two
limitations preclude the formulation of conclusions based upon
the analyses, even though it suggested that there was minimal dif-
ference experienced between using recombinant or plasma hepati-
tis B vaccines.
Only two trials compared the use of a reinforced series against
three inoculations of recombinant hepatitis B vaccine (El-Reshaid
1994; Jilg 1986a). Sample sizes from both studies were very small
(n = 106). The methodological quality for these two trials was
also deemed to be poor with both having inadequate allocation
concealment. The use of two differing doses of vaccine (20 µg and
40 µg) in a reinforced vaccination series (Jilg 1986a) may have
affected the outcome. Bias may have also been generated as the
arm of three inoculations of 40 µg in one trial was involved in two
comparisons, although the number of participants was halved. No
heterogeneitywas exhibited in this analysis.With these limitations,
no benefit was found in using a reinforced vaccination series in
the CRF population.
Only three of seven included trials were double blinded (Crosnier
1981; Desmyter 1983; Stevens 1984), all of which assessed the
use of plasma derived hepatitis B vaccine against placebo. The re-
maining trials were not blinded. Although non-blinded observers
can introduce significant yet unintentional bias into the analysis,
the important study outcomes of well-defined serologic responses
and HBV infections indicate that inadequate blinding may be of
less concern than issues relating to allocation. None of the studies
clearly described the generation of the allocation sequence. In ad-
dition, allocation concealment was found to be inadequate for all
of the studies with the exception of one (Desmyter 1983). This,
ultimately limits the interpretability of the analyses undertaken in
this review.
While this review found that the use of plasma derived hepatitis B
vaccines produced seroconversions that did not differ significantly
from recombinant derived vaccines, the current use of plasma vac-
cines is controversial. Plasma derived vaccines are human blood
products and theoretically have the potential for producing adverse
effects includingbloodborne infections.One study (Stevens 1984)
observed 101 cases of non-A, non-B hepatitis, which was likely
hepatitis C, occurring in both the plasma vaccine and placebo co-
horts.
Current practice in North American and European dialysis centres
is to use a reinforced vaccination series of four inoculations of
Engerix B (40 µg) vaccine for those over 20 years of age (Rangel
2000; CDC 2001). The results of this review do not support this
practice. However, the limited number of randomised trials, the
low methodological quality of assessed trials, and the relatively
low number of participants in these trials are obvious limitations
hindering the formulation of clear conclusions.
The ideal dosing schedule is uncertain. The current review does
not support the administration of more than three doses of vac-
cine. However, as previously discussed, there are concerns with the
quality of this finding. Given the knowledge that CRF patients
on haemodialysis have impaired immune response mechanisms
(Girndt 2002), it is prudent to determine the adequacy of vaccina-
tion in each patient following the third inoculation so that supple-
mental inoculations can be administered if needed. Further ran-
domised clinical trials of good methodological quality are needed
to resolve this issue. Additional factors that need to be considered
in determining the effectiveness of hepatitis B vaccination in this
population include the dosage of vaccine, the route of administra-
tion, and the use of adjuvants.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Plasma derived hepatitis B vaccines are clearly more effective at
achieving anti-HBs antibodies than placebo. No statistically sig-
nificant difference was found between the use of recombinant or
plasma vaccine. However, given the theoretical potential for trans-
mission of blood born pathogens with plasma derived vaccines,
recombinant vaccines remain the vaccine of choice in high-income
nations. Overall, hepatitis B vaccines, both plasma derived and
recombinant yeast derived, are effective in achieving seroconver-
sions, although two of the three studies of plasma vaccine showed
short term benefits in preventing HBV infections. This review did
not show that either vaccine prevents HBV infections in chronic
renal failure patients.
No statistically significant difference of effectiveness was observed
between reinforced vaccination series and routine vaccinations of
three inoculations using recombinant derived vaccine.
There is still insufficient information on adverse effects among
chronic renal failure patients but the data reviewed do not indicate
that vaccinations cause harm.
Implications for research
Determining the most effective method of achieving seroconver-
sion and preventing hepatitis B infections in the chronic renal
failure population using recombinant vaccines is needed since this
question has not been answered by currently available randomised
clinical trials. Future randomised clinical trials with large sample
sizes are encouraged to compare plasma derived vaccines with re-
combinant vaccines among persons with impaired immunity.
Further randomised clinical trials of high methodological qual-
ity addressing a reinforced vaccination series (three inoculations
plus one or more booster inoculations) of recombinant hepatitis
B vaccines against a vaccination series of three inoculations plus
placebo booster inoculations would be of benefit to determine the
most optimal schedule for attaining seroconversion. To date there
are insufficient randomised trials on which to formulate clinical
practice recommendations. Future directions in enhancing hep-
atitis B vaccine effectiveness in chronic renal failure patients may
involve the use of adjuvants. As this review did not assess route
of administration, or compare differing doses of vaccines, these
issues require future investigation. Future trials ought to adopt
the CONSORT Guidelines (Consolidated Standards of Report-
ing Trials) (CONSORT Statement) in their reporting.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Crosnier 1981
Methods Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.
43 dropouts.
* For assessment of methodological quality, please see Additional Table 04
Participants Haemodialysis patients.
Interventions Institut Pasteur production vaccine (plasma) 5 µg at 0,1, and 2 months versus placebo at 0,1, and 2
months
Outcomes Anti-HBs seroconversion active hepatitis B infections, and adverse events, deaths at 12 months
Notes Plasma vaccine versus placebo.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Desmyter 1983
Methods Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.
13 dropouts.
* For assessment of methodological quality, please see Additional Table 04
Participants Haemodialysis patients
(vaccine = 94 > 1 year, placebo = 80 > 1 year).
Interventions CLB (plasma) vaccine 3 µg at 0, 1, 2, and 5 versus placebo at 0, 1, 2, and 5 months
Outcomes Anti-HBs seroconversion, partial seroconversion, active hepatitis B infections, adverse events, deaths at
14 months
Notes Plasma vaccine versus placebo.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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El-Reshaid 1994
Methods Randomised clinical trial, single-blinded, withdrawals/dropouts discussed.
9 dropouts.
* For assessment of methodological quality, please see Additional Table 04
Participants Peritoneal and haemodialysis patients.
Interventions Engerix B (recombinant) 40 µg at 0, 1, and 6 versus Engerix B (recombinant) 40 µg at 0, 1, 2, and 6
months.
(Also Engerix B (recombinant) 20 µg at 0, 1, and 6 months was assessed, but this arm was excluded for the
purposes of this review as this was for healthy staff and not related to the 3 inoculation versus reinforced
series debate)
Outcomes Anti-HBs seroconversion, active infections at 24 months.
Notes Recombinant vaccine schedule.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Jilg 1986a
Methods Randomised clinical trial, not blinded.
* For assessment of methodological quality, please see Additional Table 04
Participants Dialysis patients.
Interventions Merck Sharp Dohme (recombinant) 40 µg at 0, 1, 6 versus Merck Sharp Dohme (recombinant) 40 µg at
0, 1, 2, 3, 4, and 5 months
Merck Sharp Dohme (recombinant) 40 µg at 0, 1, 6 versus Merck Sharp Dohme (recombinant) 20 µg at
0, 1, 2, 3, 4, 5
Outcomes Anti-HBs seroconversion at 10 months.
Notes Recombinant vaccine schedule (groups 1 and 3 combined).
Recombinant vaccine schedule (groups 1 and 2 combined).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Jilg 1986b
Methods Please see Jilg 1986a
Participants
Interventions
Outcomes
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Jungers 1994a
Methods Randomised clinical trial, withdrawals/dropouts discussed.
16 dropouts.
(Not blinded)
* For assessment of methodological quality, please see Additional Table 04
Participants Chronic uremic patients (not on dialysis).
Interventions Hevac B (plasma) vaccine 5 µg at 0, 1, 2, 4, and 12 months versus GenHevac B (recombinant) vaccine
20 µg at 0, 1, 2, 4, and 12 months
Outcomes Anti-HBs seroconversion, partial seroconversion at 12 months
Notes Recombinant versus plasma.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Seaworth 1988a
Methods Randomised clinical trial, withdrawals/dropouts, discussed.
8 dropouts.
(Not blinded)
* For assessment of methodological quality, please see Additional Table 04
Participants Chronic renal failure patients (mean 4.5 mg/dL, range 2.0 to 9.8)
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Seaworth 1988a (Continued)
Interventions Recombivax (recombinant) vaccine 20 ug at 0, 1, 6 months versus recombivax (recombinant) vaccine 40
ug at 0, 1, 6 months versus heptavax B (plasma) vaccine 40 µg at 0, 1, 6 months
Outcomes Anti-HBs seroconversion, partial seroconversion, deaths at 12 months
Notes Recombinant versus plasma (groups 1 and 3 combined).
Recombinant versus plasma (groups 2 and 3 combined).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Seaworth 1988b
Methods Please see Seaworth 1988a
Participants
Interventions
Outcomes
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Stevens 1984
Methods Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.
98 dropouts.
* For assessment of methodological quality, please see Additional Table 04
Participants Haemodialysis patients
N = 1311.
Interventions Heptavax B (plasma) vaccine 40 µg at 0, 1, and 6 months versus placebo at 0, 1, and 6 months
Outcomes Anti-HBs seroconversion, active hepatitis B infections, deaths at 24 months
Notes Plasma versus placebo.
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Stevens 1984 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andre 1987 A randomised clinical trial of 6100 people of which 270 were on chronic haemodialysis (plasma derived vaccine
20 µg at 0, 1, and 6 months or 0, 1, 2, and 12 months versus recombinant vaccine 2.5 µg, 5 µg, 10 µg, 20 µg
at 0, 1, and 6 months or 0, 1, 2, and 12 months).
We were unable to extract data specific to haemodialysis patients from the results presented in this publication
Chang 1996 A randomised clinical trial of recombinant vaccine of different doses, schedules, and routes (HepB-DNA 40 µg
at 0,1,and 3 months intramuscularly versus HepB-DNA 10 µg at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 months
intracutaneously). This trial was excluded because it assessed route of vaccine administration
Charest 2000 A randomised clinical trial of recombinant vaccines of different routes, doses, and schedules (Engerix B 40 µg
at 0, 1, 2, and 6 months intramuscularly versus recombinant hepatitis B vaccine 5 µg intradermally at 0 month;
then every two weeks until adequate titres at least 1000 IU/L or until 2 years). This trial was excluded because
it assessed route of vaccine administration
Jungers 1994b A randomised clinical trial of recombinant vaccine with interleukin-2 among non-responders. This trial involved
the use of an adjuvant and was therefore excluded
Propst 1998 A randomised clinical trial of recombinant vaccine of different dose, schedule, and route (Engerix B 40 µg
IM at 0, 1, and 6 months and booster at 8 and 12 months if titres less than 10 IU/L versus Engerix B 20 µg
subcutaneously every two weeks up to 240 µg versus Engerix B 20 µg intradermally every 2 weeks up to 240
µg). This trial was excluded because it assessed route of vaccine administration
Vincent 1998 A randomised clinical trial of recombinant vaccine of different dose, route and schedule (40 µg intramuscularly
at 0, 4, and 8 months versus 20 µg intradermally at 0, 0.25, 0.5, 0.75, 1, and 1.25 months). This trial was
excluded because it assessed route of vaccine administration
Vlassopoulos 1999 A randomised clinical trial of recombinant vaccine of different dose, route and schedule (Engerix, SKB 5 µg
intradermally at 0, 0.5, 1, 1.5, 2, 2.5, 3, and 3.5 months and intramuscular booster at 12 versus Engerix, SKB
20 µg intramuscularly at 0, 1, 2, and 12 months). This trial was excluded because it assessed route of vaccine
administration
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D A T A A N D A N A L Y S E S
Comparison 1. Plasma vaccine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seroconversion to anti-HBs 3 1850 Risk Ratio (M-H, Random, 95% CI) 23.00 [14.39, 36.76]
2 Full and partial anti-HBs
seroconversion
1 401 Risk Ratio (M-H, Random, 95% CI) 21.52 [10.89, 42.52]
3 Hepatitis B virus infection 3 1850 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.20, 1.24]
4 Adverse events 2 539 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.25, 2.05]
5 Deaths 2 539 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.79, 2.44]
6 Sensitivity analysis for hepatitis
B virus (HBV) infection
excluding Stevens 1984
2 539 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.18, 0.62]
Comparison 2. Recombinant vaccine versus plasma vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Anti-HBs seroconversion 3 181 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.28, 1.53]
2 Full and partial seroconversion
to anti-HBs
3 181 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.69, 1.38]
3 Sensitivity analysis for anti-HBs
seroconversion - combining
both recombinant arms of
Seaworth 1988
2 181 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.29, 1.92]
4 Sensitivity analysis for anti-HBs
seroconversion (excluding the
low dose recombinant arm of
Seaworth 1988)
2 160 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.58, 1.57]
Comparison 3. Reinforced recombinant vaccination series versus primary recombinant vaccination series
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seroconversion to anti-HBs 3 106 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.85, 2.16]
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Analysis 1.1. Comparison 1 Plasma vaccine versus placebo, Outcome 1 Seroconversion to anti-HBs.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 1 Plasma vaccine versus placebo
Outcome: 1 Seroconversion to anti-HBs
Study or subgroup Plasma vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crosnier 1981 26/72 0/66 2.8 % 48.64 [ 3.02, 782.61 ]
Desmyter 1983 148/201 6/200 35.0 % 24.54 [ 11.11, 54.21 ]
Stevens 1984 239/660 11/651 62.2 % 21.43 [ 11.83, 38.84 ]
Total (95% CI) 933 917 100.0 % 23.00 [ 14.39, 36.76 ]
Total events: 413 (Plasma vaccine), 17 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 13.11 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours Plasma
Analysis 1.2. Comparison 1 Plasma vaccine versus placebo, Outcome 2 Full and partial anti-HBs
seroconversion.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 1 Plasma vaccine versus placebo
Outcome: 2 Full and partial anti-HBs seroconversion
Study or subgroup Plasma vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Desmyter 1983 173/201 8/200 100.0 % 21.52 [ 10.89, 42.52 ]
Total (95% CI) 201 200 100.0 % 21.52 [ 10.89, 42.52 ]
Total events: 173 (Plasma vaccine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 8.83 (P < 0.00001)
0.01 0.1 1 10 100
Favours Placebo Favours Plasma
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Analysis 1.3. Comparison 1 Plasma vaccine versus placebo, Outcome 3 Hepatitis B virus infection.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 1 Plasma vaccine versus placebo
Outcome: 3 Hepatitis B virus infection
Study or subgroup Plasma vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crosnier 1981 10/72 21/66 32.9 % 0.44 [ 0.22, 0.86 ]
Desmyter 1983 7/201 30/200 30.7 % 0.23 [ 0.10, 0.52 ]
Stevens 1984 35/660 32/651 36.3 % 1.08 [ 0.68, 1.72 ]
Total (95% CI) 933 917 100.0 % 0.50 [ 0.20, 1.24 ]
Total events: 52 (Plasma vaccine), 83 (Placebo)
Heterogeneity: Tau2 = 0.54; Chi2 = 12.29, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 1.49 (P = 0.14)
0.1 0.2 0.5 1 2 5 10
Favours Plasma Favours Placebo
Analysis 1.4. Comparison 1 Plasma vaccine versus placebo, Outcome 4 Adverse events.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 1 Plasma vaccine versus placebo
Outcome: 4 Adverse events
Study or subgroup Plasma vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crosnier 1981 2/72 6/66 28.1 % 0.31 [ 0.06, 1.46 ]
Desmyter 1983 111/201 111/200 71.9 % 1.00 [ 0.83, 1.19 ]
Total (95% CI) 273 266 100.0 % 0.71 [ 0.25, 2.05 ]
Total events: 113 (Plasma vaccine), 117 (Placebo)
Heterogeneity: Tau2 = 0.40; Chi2 = 2.22, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.62 (P = 0.53)
0.01 0.1 1 10 100
Favours Plasma Favours Placebo
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Analysis 1.5. Comparison 1 Plasma vaccine versus placebo, Outcome 5 Deaths.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 1 Plasma vaccine versus placebo
Outcome: 5 Deaths
Study or subgroup Plasma vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crosnier 1981 5/72 3/66 16.3 % 1.53 [ 0.38, 6.15 ]
Desmyter 1983 22/201 16/200 83.7 % 1.37 [ 0.74, 2.53 ]
Total (95% CI) 273 266 100.0 % 1.39 [ 0.79, 2.44 ]
Total events: 27 (Plasma vaccine), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
0.1 0.2 0.5 1 2 5 10
Favours Plasma Favours Placebo
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Analysis 1.6. Comparison 1 Plasma vaccine versus placebo, Outcome 6 Sensitivity analysis for hepatitis B
virus (HBV) infection excluding Stevens 1984.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 1 Plasma vaccine versus placebo
Outcome: 6 Sensitivity analysis for hepatitis B virus (HBV) infection excluding Stevens 1984
Study or subgroup Plasma vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crosnier 1981 10/72 21/66 55.8 % 0.44 [ 0.22, 0.86 ]
Desmyter 1983 7/201 30/200 44.2 % 0.23 [ 0.10, 0.52 ]
Total (95% CI) 273 266 100.0 % 0.33 [ 0.18, 0.62 ]
Total events: 17 (Plasma vaccine), 51 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 3.48 (P = 0.00049)
0.01 0.1 1 10 100
Favours Plasma Favours Placebo
Analysis 2.1. Comparison 2 Recombinant vaccine versus plasma vaccine, Outcome 1 Anti-HBs
seroconversion.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 2 Recombinant vaccine versus plasma vaccine
Outcome: 1 Anti-HBs seroconversion
Study or subgroup Recombinant vaccine Plasma vaccine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jungers 1994a 43/60 37/60 41.8 % 1.16 [ 0.90, 1.50 ]
Seaworth 1988a 9/20 6/10 33.5 % 0.75 [ 0.37, 1.51 ]
Seaworth 1988b 3/21 7/10 24.7 % 0.20 [ 0.07, 0.63 ]
Total (95% CI) 101 80 100.0 % 0.65 [ 0.28, 1.53 ]
Total events: 55 (Recombinant vaccine), 50 (Plasma vaccine)
Heterogeneity: Tau2 = 0.43; Chi2 = 10.22, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 0.98 (P = 0.33)
0.1 0.2 0.5 1 2 5 10
Favours Plasma Favours Recombinant
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Analysis 2.2. Comparison 2 Recombinant vaccine versus plasma vaccine, Outcome 2 Full and partial
seroconversion to anti-HBs.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 2 Recombinant vaccine versus plasma vaccine
Outcome: 2 Full and partial seroconversion to anti-HBs
Study or subgroup Recombinant vaccine Plasma vaccine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jungers 1994a 48/60 40/60 52.4 % 1.20 [ 0.96, 1.49 ]
Seaworth 1988a 12/20 7/10 25.5 % 0.86 [ 0.50, 1.47 ]
Seaworth 1988b 10/21 7/10 22.1 % 0.68 [ 0.37, 1.25 ]
Total (95% CI) 101 80 100.0 % 0.97 [ 0.69, 1.38 ]
Total events: 70 (Recombinant vaccine), 54 (Plasma vaccine)
Heterogeneity: Tau2 = 0.05; Chi2 = 3.88, df = 2 (P = 0.14); I2 =48%
Test for overall effect: Z = 0.16 (P = 0.87)
0.01 0.1 1 10 100
Favours Plasma Favours Recombinant
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Analysis 2.3. Comparison 2 Recombinant vaccine versus plasma vaccine, Outcome 3 Sensitivity analysis for
anti-HBs seroconversion - combining both recombinant arms of Seaworth 1988.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 2 Recombinant vaccine versus plasma vaccine
Outcome: 3 Sensitivity analysis for anti-HBs seroconversion - combining both recombinant arms of Seaworth 1988
Study or subgroup Recombinant vaccine Plasma vaccine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jungers 1994a 43/60 37/60 53.7 % 1.16 [ 0.90, 1.50 ]
Seaworth 1988a 12/41 13/20 46.3 % 0.45 [ 0.25, 0.80 ]
Total (95% CI) 101 80 100.0 % 0.75 [ 0.29, 1.92 ]
Total events: 55 (Recombinant vaccine), 50 (Plasma vaccine)
Heterogeneity: Tau2 = 0.41; Chi2 = 9.02, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.60 (P = 0.55)
0.1 0.2 0.5 1 2 5 10
Favours Plasma Favours Recombinant
Analysis 2.4. Comparison 2 Recombinant vaccine versus plasma vaccine, Outcome 4 Sensitivity analysis for
anti-HBs seroconversion (excluding the low dose recombinant arm of Seaworth 1988).
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 2 Recombinant vaccine versus plasma vaccine
Outcome: 4 Sensitivity analysis for anti-HBs seroconversion (excluding the low dose recombinant arm of Seaworth 1988)
Study or subgroup Recombinant vaccine Plasma vaccine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jungers 1994a 43/60 37/60 63.0 % 1.16 [ 0.90, 1.50 ]
Seaworth 1988a 9/20 13/20 37.0 % 0.69 [ 0.39, 1.24 ]
Total (95% CI) 80 80 100.0 % 0.96 [ 0.58, 1.57 ]
Total events: 52 (Recombinant vaccine), 50 (Plasma vaccine)
Heterogeneity: Tau2 = 0.08; Chi2 = 2.61, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 0.16 (P = 0.87)
0.1 0.2 0.5 1 2 5 10
Favours Plasma Favours Recombinant
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Analysis 3.1. Comparison 3 Reinforced recombinant vaccination series versus primary recombinant
vaccination series, Outcome 1 Seroconversion to anti-HBs.
Review: Hepatitis B vaccination for patients with chronic renal failure
Comparison: 3 Reinforced recombinant vaccination series versus primary recombinant vaccination series
Outcome: 1 Seroconversion to anti-HBs
Study or subgroup Reinforced series Primary series Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
El-Reshaid 1994 15/24 7/24 34.4 % 2.14 [ 1.07, 4.30 ]
Jilg 1986a 12/20 5/9 35.2 % 1.08 [ 0.54, 2.14 ]
Jilg 1986b 10/19 5/10 30.4 % 1.05 [ 0.50, 2.23 ]
Total (95% CI) 63 43 100.0 % 1.36 [ 0.85, 2.16 ]
Total events: 37 (Reinforced series), 17 (Primary series)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 1.28 (P = 0.20)
0.2 0.5 1 2 5
Favours Standard Favours Reinforced
A D D I T I O N A L T A B L E S
Table 1. Criteria for assessing anti-HBs response (North America)
Response Sample ratio units (SRU) International units (IU/L)
Inadequate 2.1 - 9.9 SRU 2.1 - 9.9 IU/L
Adequate > 10 SRU > 10 IU/L
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Table 2. Criteria for assessing anti-HBs response (Europe)
Response Sample ratio units (SRU) International units (IU/L)
Inadequate 2.1 - 9.9 SRU 2.1 - 9.9 IU/L
Low response 10 - 100 IU/L
Adequate > 10 SRU > 100 IU/L
Table 3. Methodological quality of included studies
Included study Generation of allocation
sequence
Allocation concealment Blinding Follow-up
Crosnier 1981 Unclear - not described. Unclear Adequate double blinded
and placebo controlled.
Number and reason for
dropouts and withdrawals
mentioned.
Desmyter 1983 Unclear - not described. A
code was used, however,
this was insufficient infor-
mation to determine ap-
propriateness
Adequate. An indepen-
dent physician had sole ac-
cess to the code
Adequate double blinded
and placebo controlled.
Number and reason for
dropouts described.
El-Reshaid 1994 Unclear - not described. Unclear Not double blinded. Number of dropouts and
withdrawals given but not
reasons.
Jilg 1986 Unclear - not described. Unclear Not double blinded. Number and reasons for
dropouts and withdrawals
not reported
Jungers 1994 Unclear - not described. Unclear Not double blinded. Number and reasons for
dropouts and withdrawals
mentioned.
Seaworth 1988 Unclear - not described. Unclear Not double blinded. Number and reasons for
dropouts and withdrawals
described.
Stevens 1984 Unclear - not described. Unclear Adequate double blinded
and placebo controlled.
Number and reasons for
dropouts and withdrawals
described.
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A P P E N D I C E S
Appendix 1. Search Strategies
Database Search strategy Search performed
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
(’renal failure’ or ’kidney failure’ or ’renal
disease’ or ’kidney disease’ or dialysis or
h*emodialysis) and ’hepatitis b’ and (vac-
cin* or immun* or booster or re-vaccin*
or revaccin*) or (engerix or heptavax or re-
combivax)
October 2002
PubMed/MEDLINE MESH Terms kidney[MESH]; renal dial-
ysis[MESH]; dialysis[MESH], peritoneal
dialysis, continuous ambulatory[MESH];
dialysis, peritoneal[MESH]; kidney failure,
chronic[MESH}; kidney failure[MESH];
uremia[MESH]; hepatitis B[MESH]; hep-
atitis B surface antigens[MESH]; anti-
gens, surface[MESH]; hepatitis B core
antigens[MESH]; hepatitis B e anti-
gens[MESH]; hepatitis B surface anti-
gens[MESH]; vaccine[MESH]; hepatitis
B vaccines[MESH]; vaccination[MESH];
immunization, secondary[MESH]; im-
munity[MESH]; immune sera[MESH];
vaccine, hepatitis B[MESH]; adjuvants,
immunologic[MESH]; adjuvants, phar-
maceutic[MESH]; randomized controlled
trial[MESH]
July 2003
PubMed/MEDLINE Search Strategy (renal OR kidney OR kidney[MESH]
OR “renal dialysis”[MESH] OR dialysis
OR dialysis[MESH] OR hemodialysis OR
haemodialysis ORCAPDOR “continuous
ambulatory peritoneal dialysis” ORCCPD
OR “continuous cyclical peritoneal dialy-
sis” OR ESRD OR “end stage renal dis-
ease” OR “chronic renal failure” OR “renal
failure”ORESRFOR “end stage renal fail-
ure” OR “chronic renal insufficiency” OR
“renal insufficiency” OR “peritoneal dial-
ysis, continuous ambulatory”[MESH] OR
“dialysis, peritoneal”[MESH] OR “kid-
ney failure, chronic”[MESH] OR “kidney
failure”[MESH] OR uremia OR uraemia
OR uremic OR uremia[MESH]) AND
( “hepatitis b” OR “hepatitis B”[MESH]
July 2003
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(Continued)
OR “australian antigen” OR HBSAG OR
“surface antigen” OR “hepatitis b sur-
face antigens”[MESH] OR “antigens, sur-
face”[MESH] OR “hepatitis b core anti-
gens”[MESH] OR “hepatitis b e anti-
gens”[MESH]OR“hepatitis b surface anti-
gens”[MESH]) AND ( vaccine[MESH]
OR vaccin* OR immun* OR booster OR
“re-vaccinat*” OR revaccinat* OR engerix
OR heptavax OR recombivax OR “hepati-
tis b vaccines”[MESH]OR“secondary vac-
cination” OR “viral vaccines”[MESH] OR
“viral hepatitis vaccines”[MESH] OR vac-
cination[MESH] OR “immunization, sec-
ondary”[MESH] OR immunity[MESH]
OR “immune sera”[MESH] OR “vaccine,
hepatitis b”[MESH] OR adjuvant* OR
“Adjuvants, Immunologic”[MESH] OR
“Adjuvants, Pharmaceutic”[MESH])AND
(“trial” OR “clinical trial” OR “random-
ized controlled trial”OR “randomised con-
trolled trial” OR “randomized controlled
trial”[MESH] OR “randomized controlled
trial.pt” OR review[pt])
EMBASE #1 explode “chronic-kidney-disease”/ all
subheadings
#2 explode “chronic-kidney-failure”/ all
subheadings
#3 explode “kidney”/ all subheadings
#4 explode “kidney-disease”/ all subhead-
ings
#5 explode “kidney-failure”/ all subhead-
ings
#6 explode “hemodialysis”/ all subhead-
ings
#7 explode “continuous-ambulatory-peri-
toneal-dialysis”/ all subheadings
#8 explode “dialysis”/ all subheadings
#9 explode “peritoneal-dialysis”/ all sub-
headings
#10 explode “uremia”/ all subheadings
#11 (renal or kidney) and (failure or dis-
ease* or insufficien*)
#12 ur*emi*
#13 dialys*
#14 h*emodialys*
#15 CAPD or CCPD or ESRD or ESRF
#16 #1 or #2 or #3 or #4 or #5 or #6 or #
13 November 2003
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(Continued)
7 or #8 or #9 or #10 or #11 or #12 or #13
or #14 or #15
#17 explode “hepatitis-B”/ all subheadings
#18 explode “hepatitis-B-antigen”/ all sub-
headings
#19 explode “hepatitis-B-core-antigen”/ all
subheadings
#20 explode “hepatitis-Be-antigen”/ all
subheadings
#21 explode “hepatitis-B-surface-antigen”/
all subheadings
#22 hepatitis B
#23 australian antigen
#24 HBsAg
#25 surface antigen*
#26 #17 or #18 or #19 or #20 or #21 or #
22 or #23 or #24 or #25
#27 explode “hepatitis-B-vaccine”/ all sub-
headings
#28 explode “vaccine”/ all subheadings
#29 explode “vaccination”/ all subheadings
#30 explode “immunization”/ all subhead-
ings
#31 explode “immunity”/ all subheadings
#32 explode “antiserum”/ all subheadings
#33 vaccin* or immun* or booster or
re*vaccin*
#34 #27 or #28 or #29 or #30 or #31 or #
32 or #33
#35 #26 and #34
#36 energix or heptavax or recombivax
#37 #35 or #36
#38 #16 and #37
#39 random* or blind* or placebo or meta-
analysis
#40 #38 and #39
WH A T ’ S N E W
Last assessed as up-to-date: 23 May 2004.
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Date Event Description
9 November 2008 Amended Converted to new review format.
H I S T O R Y
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Review first published: Issue 3, 2004
C O N T R I B U T I O N S O F A U T H O R S
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D E C L A R A T I O N S O F I N T E R E S T
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S O U R C E S O F S U P P O R T
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External sources
• No sources of support supplied
I N D E X T E R M S
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